NK1 receptor antagonists: all 244 studies that test it

Page 3 of 3. Open to participants first (12), then studies with results posted, then the rest; newest registration first within each.

• The Effects Of GW679769 (Casopitant) On The Pharmacokinetics Of Docetaxel In Subjects With CancerCompletedNCT00440128Phase 1
• A Study to Assess the Safety & Interaction Between GW679769, Dexamethasone, & Ondansetron When Taken by Healthy AdultsCompletedNCT00437229Phase 1
• A Study of the Drug Casopitant for the Prevention of Nausea Caused By Cisplatin-Based Highly Emetogenic ChemotherapyCompletedNCT00431236Phase 3
• Pharmacokinetic Study of Aprepitant in BEP Treatment of Patients With Testis Carcinoma (A-BEP)WithdrawnNCT00429754Phase 4
• Effects of Treatment With Aprepitant (Emend®) in HIV Infected IndividualsCompletedNCT00428519Phase 1
• AMENO-2: Aprepitant Plus Palonosetron Versus Granisetron in the Prevention of Nausea and the Emesis Induced by Chemotherapy in Patients Treated With Haematopoietic ProgenitorsCompletedNCT00415103Phase 4
• Study Of The Effects Of A New Antidepressant Therapy In Patients With Major Depressive Disorder (MDD)CompletedNCT00413023Phase 2
• A Study in Healthy Subjects to Assess How Dosing of Rifampin Affects What the Body Does to a Dose of GW679769 (Casopitant).CompletedNCT00405080Phase 1
• Study Of Healthy Subjects To Assess The Effect Of Ketoconazole And The Way The Body Will React To Casopitant [GW679769]CompletedNCT00404378Phase 1
• A Study Testing the Effect and Safety of Casopitant (GW679769) While Taking Warfarin in Healthy Human VolunteersCompletedNCT00404274Phase 1
• A Combination Therapy In Patients With Social Anxiety DisorderCompletedNCT00403962Phase 2
• A Multicenter, Randomized, Controlled Trial of SCH 619734 for the Treatment of Chemotherapy-Induced Nausea and Vomiting (Study P04351AM2)(COMPLETED)CompletedNCT00394966Phase 2
• Vestipitant Or Vestipitant/Paroxetine Combination In Subjects With Tinnitus And Hearing Loss.CompletedNCT00394056Phase 2
• Intravenous And Oral Casopitant (GW679769) For The Prevention Of Chemotherapy Induced Nausea And VomitingCompletedNCT00366834Phase 3
• Observational Study Evaluating The Processing Or Breakdown Of GW679769 In Subjects With Hepatic ImpairmentCompletedNCT00359177Phase 1
• Observational Pharmacokinetic Study Of GW679769 In Subjects With Renal ImpairmentCompletedNCT00358813Phase 1
• An Exploratory Study Examining The Effects Of Taking GW679769 Once-Daily For 4 Days In Patients With Functional DyspepsiaCompletedNCT00358410Phase 2
• Evaluation of A Morning Dosing Of A New Medicine And Its Effects On Sleep At Bedtime In Subjects With Primary InsomniaCompletedNCT00354809Phase 2
• Cyclophosphamide Drug Interaction Study In Cancer PatientsTerminatedNCT00334646Phase 1
• Casopitant And ZOFRAN To Prevent Post Operative Nausea And Vomiting In WomenCompletedNCT00334152Phase 3
• Effects Of GW679769 On Bladder Nerve Function And Symptoms Of Overactive Bladder In Spinal Cord Injury PatientsTerminatedNCT00332319Phase 2
• fMRI Study Comparing BOLD Activation Patterns Using GW679769 In Subjects With Social Anxiety DisorderCompletedNCT00332046Phase 1
• Casopitant (Oral) And ZOFRAN To Prevent Postoperative Nausea And Vomiting In WomenCompletedNCT00326248Phase 3
• A Study Of GW679769 Compared To Placebo In Women With Overactive BladderCompletedNCT00321477Phase 2
• Efficacy & Safety of the Oral Neurokinin-1 Antagonist, Aprepitant, in Combo With Ondansetron & Dexamethasone in Patients Undergoing Auto Peripheral Blood Stem Cell TransplantationCompletedNCT00314743Early Phase 1
• Safety and Efficacy of MK0594 to Treat Overactive Bladder (0594-003)CompletedNCT00290563Phase 2
• Effects Of GW679769 On Sleep Onset And Maintenance,And Next Day Functioning In The Elderly And Non-elderly With Primary InsomniaCompletedNCT00280436Phase 2
• Effects Of GW679769 On Sleep Onset And Maintenance And Next Day Functioning In Subjects With Primary InsomniaCompletedNCT00280423Phase 2
• Post-Operative Nausea And Vomiting Study In Female PatientsCompletedNCT00274690Phase 2
• ONO-7436 Phase II Study in JapanCompletedNCT00212602Phase 2
• Study for The Prevention Of Nausea in Cancer Patients Receiving Highly Emetogenic Cisplatin Based ChemotherapyCompletedNCT00169572Phase 2
• Study Of Prevention of Chemo-Induced Nausea and Vomiting Caused By Moderately Emetogenic ChemotherapyCompletedNCT00104403Phase 2
• Study Of GW679769 In Major Depressive DisorderCompletedNCT00102492Phase 2
• Study of Aprepitant (MK-0869) for Chemotherapy-Induced Nausea and Vomiting (CINV) in Adolescent Participants (MK-0869-097)CompletedNCT00080444Phase 3
• Treatment of Patients With Major Depressive Disorder With MK0869 (0869-062)(COMPLETED)CompletedNCT00048607Phase 3
• Long Term Treatment of Patients With Major Depressive Disorder With MK0869 (0869-065)(COMPLETED)CompletedNCT00048594Phase 3
• A Study Of A New Medicine (GW597599B) For The Treatment Of Major Depressive DisorderCompletedNCT00048204Phase 2
• Treatment of Patients With Major Depressive Disorder With MK0869 (0869-073)CompletedNCT00042029Phase 3
• Treatment of Patients With Major Depressive Disorder With MK0869 (0869-061)CompletedNCT00035295Phase 3
• Treatment of Patients With Major Depressive Disorder With MK0869 (0869-060)(COMPLETED)CompletedNCT00035282Phase 3
• Treatment of Patients With Major Depressive Disorder With MK0869 (0869-068)(COMPLETED)CompletedNCT00035048Phase 3
• Treatment of Patients With Major Depressive Disorder With MK0869 (0869-059)CompletedNCT00035009Phase 3
• Treatment of Patients With Major Depressive Disorder With MK0869 (0869-066)(COMPLETED)CompletedNCT00034983Phase 3
• Treatment of Patients With Major Depressive Disorder With MK0869 (0869-063)CompletedNCT00034944Phase 3

← NK1 receptor antagonists overview